1. Home
  2. YJ vs GLTO Comparison

YJ vs GLTO Comparison

Compare YJ & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

HOLD

Current Price

$1.40

Market Cap

7.4M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

N/A

Current Price

$28.89

Market Cap

23.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YJ
GLTO
Founded
2015
2011
Country
China
Denmark
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
23.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
YJ
GLTO
Price
$1.40
$28.89
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
2.7K
157.4K
Earning Date
11-25-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$47,760,127.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$2.01
52 Week High
$2.67
$33.60

Technical Indicators

Market Signals
Indicator
YJ
GLTO
Relative Strength Index (RSI) 33.31 69.39
Support Level $1.51 $25.60
Resistance Level $1.66 $32.55
Average True Range (ATR) 0.05 3.39
MACD 0.00 0.49
Stochastic Oscillator 3.69 90.22

Price Performance

Historical Comparison
YJ
GLTO

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: